Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset
As Firm Reprioritizes Resources
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial of atacicept lifted hopes for the product’s prospects as compared with a key rival candidate.
